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aimed to compare regular drug-eluting stents
versus the dedicated coronary bifurcation
sirolimus-eluting BiOSS LIM C stent
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Abstract
Introduction: Coronary bifurcations are encountered in about 15% to 20% of percutaneous coronary interventions (PCIs). They
are considered technically challenging and associated with worse clinical outcomes than nonbifurcation lesions. The BiOSS LIM C is
a dedicated bifurcation balloon expandable stent made of cobalt-chromium alloy (strut thickness 70mm) releasing sirolimus (1.4mg/
mm2) from the surface of a biodegradable coating comprised of a copolymer of lactic and glycolic acids.
Conclusion:The aim of the randomized, multicenter, open-label, controlled POLBOS III trial is to compare BiOSS LIM C with limus
second-generation drug-eluting stents (DES) in the treatment of non-left main stem coronary bifurcations (ClinicalTrials.gov
NCT03548272).
Abbreviations: ACS = acute coronary syndrome, ASA = acetylsalicylic acid, DES = drug eluting stent, DOT = distal optimization
technique, LM = left main stem, MACE = major adverse cardiovascular event, NC = noncomplaint, NSTE-ACS = non-ST elevation
acute coronary syndrome, PCI= percutaneous coronary intervention, PGLA= copolymer of lactic and glycolic acids, POT= proximal
optimization technique, PTS = provisional T-stenting, QCA = quantitative coronary angiography, ULN = upper limit normal.
Keywords: BiOSS LIM C, coronary bifurcations, non-LM, sirolimus-eluting stent
1. Introduction
The BiOSS (Bifurcation Optimization Stent System) Clinical
Program has started in 2008. The first BiOSS stent was a bare
metal one (stainless steel), but shortly after a paclitaxel-eluting
version was introduced into the market—the BiOSS Expert stent
(CEMark 2010), and in 2012, sirolimus-eluting BiOSS LIM stent
was developed. The obtained results both in registries and clinical
randomized trials POLBOS I and POLBOS II[1–6] as well as in
everyday practice were satisfactory,[7–9] but still a way for
improvement has been looking for. Relatively large neointimal
growth associated with thick struts (120mm) was a reason to
design a cobalt-chromium sirolimus-eluting version—BiOSS LIM
C stent. BiOSS LIM C stent preclinical and preliminary clinical
utility has been already confirmed.[10,11]
The aim of this trial (POLBOS 3) is to compare BiOSS LIM C
with the limus second-generation drug-eluting stents (DES) in the
treatment of nonleft main (non-LM) coronary bifurcations.
2. Material and methods
2.1. Device
The BiOSS LIM C is a dedicated bifurcation balloon expandable
stent made of cobalt-chromium alloy (strut thickness 70mm)
releasing sirolimus (1.4mg/mm2) from the surface of a biode-
gradable coating comprised of a copolymer of lactic and glycolic
acids (PGLA). The degradation of the polymer lasts approxi-
mately 8 weeks. The BiOSS LIM C stent consists of 2 main
separate parts with different diameters: wider proximally and
distally smaller. The proximal part is always a shorter than the
distal one (45% vs 55%, respectively). The ratio of the proximal
part to the distal one varies between 1.15 and 1.3, ensuring
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physiological compatibility and optimal flow conditions. There is
a 2.0 to 2.4mm middle zone with 2 connecting struts after the
BiOSS stent implantation. This zone ensures “self–positioning”
of a stent after balloon deflation, as well as the opening to side
branch. There are 3 lengths (16, 19, and 24mm) of BiOSS stents
available on the market. The nominal foreshortening of the stent
is less than 0.5% and the stent strut/vessel area ratio varies
between 15% and 18%.[12]
2.2. Study population and study design
Five hundred eighteen patients with symptomatic stable coronary
artery disease or NSTE-ACS qualified for PCI in non-LM
coronary bifurcation will be screened, and enrolled if informed
consent form is signed and all inclusion criteria and none
exclusion criteria are met. Inclusion criteria and exclusion criteria
are detailed in Table 1.
Subjects will be 1:1 randomized to a BiOSS LIM C stent versus
DES group. The following DES will be allowed: Xience (Abbott
Laboratories, Chicago, IL), Resolute Onyx (Medtronic, Dublin,
Ireland), Orsiro (Biotronik, Berlin, Germany), and Synergy (Boston
Scientific, Marlborough, MA). Patients will be followed, according
to the protocol (ClinicalTrials.gov NCT03548272) (Fig. 1). Study
protocol is compliantwith SPIRITguidelines.[13] IndependentEthics
Committee approved the study protocol (No. 14/2018).
2.3. Study methodology
Single stent implantation in the main vessel-main branch across a
side branch is the default strategy (provisional T-stenting, PTS) in
all patients enrolled. Bifurcation lesions are assessed according to
Medina classification using an index of 1 for stenosis greater than
50% and 0 for no stenosis (visual estimation).[14] There is no
restriction regarding lesion length in patient selection. If required,
additional stent can be implanted (Alex Plus in the BiOSS Lim C
Group).[15] A stent in a side branch (Alex Plus in the BiOSS Lim C
Group) should be implanted only if there is proximal residual
stenosis greater than 70% after balloon dilatation and/or
significant flow impairment after main vessel—main branch
stenting and/or a flow-limiting dissection.
The implantation protocol for bifurcation is as follows:
(1) wiring of both branches;
(2) main vessel predilatation according to the operator’s decision
(recommendation BA/MB ratio close to 1:1);
(3) side branch predilatation according to operator’s decision,
however with small balloon;
(4) stent implantation (inflation for at least 20seconds);
(5) proximal optimization technique (POT);
(6) side branch postdilatation or side branch stent implantation if
necessary (proximal residual stenosis greater than 70% after
balloon dilatation and/or significant flow impairment after
main vessel—main branch stenting and/or a flow-limiting
dissection);
(7) final kissing balloon inflation at operator’s discretion
(mandatory only if 2-stent technique applied);
(8) Second POT (re-POT)
(9) Additional dilatation of a distal part of a stent (distal
optimization technique - DOT) with a NC balloon at
operator’s discretion.
In patients with ACS, loading dose of ticagrelor (180mg) or
clopidogrel (600mg) will be given, and if needed also the loading
dose of acetylsalicylic acid (ASA) was applied (300mg). In
planned procedures, 72hours before PCI, each patient will
receive ASA (75mg/24h) and clopidogrel (75mg/24h). All
procedures will be performed in a standard way via radial or
femoral access using 6 or 7 Fr guiding catheters. After insertion of
the arterial sheath, each patient received unfractionated heparin
(100IU/kg). Additional bolus will be given to maintain an
activated clotting time > 250seconds. Dual antiplatelet therapy
(ASA 75mg q.d. quaque die (once a day) and clopidogrel 75mg
q.d. or ticagrelor 90mg b.i.d. bis in die (twice a day)) will be
prescribed for 12 months.
All patients will have TnI, CK, and CK-MB levels examined
before the procedure, 6 and 24hours after. Periprocedural
myocardial infarction (type 4a) will be assessed according to the
third universal definition (patients with NSTEMI were excluded
from this assessment).[16]
Quantitative coronary angiography (QCA) analysis before and
after the procedure will be performed with the use of the
dedicated bifurcation QCA software (CAAS 11.0; Pie Medical
Imaging, Maastricht, the Netherlands).
2.4. Follow-up
Clinical visits will be performed at 30 days and 12 months, and
telephone visit will be performed at 3 and 6 months. At the
clinical follow-up visit, clinical status (Canadian Cardiovascular
Society Classification), adverse events according to protocol,
hospitalization, and medication intake will be evaluated.
2.5. Endpoints
The primary endpoint is the rate of major cardiovascular events rate
(cardiac death, myocardial infarction, target lesion revasculariza-
tion) at12months.The secondary endpoints areas follows: all-cause
death; cardiovascular death—all deaths considered cardiovascular
death if not proved otherwise; myocardial infarction—more than 5
Table 1
Inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
1. Subject at least 18 years of age. 1. Noncardiac comorbid conditions are
present with life expectancy <1 y
or that may result in protocol
noncompliance (per site
investigator’s medical judgment).
2. Subject able to verbally confirm
understandings of risks, benefits of
receiving PCI for true bifurcation
lesions, and he/she or his/her legally
authorized representative provides
written informed consent before any
study-related procedure.
2. Subjects who refuse to give
informed consent.
3. Target main branch lesion(s) located
in a native coronary artery with
diameter of ≥2.5 and 4.5mm.
Target side branch lesion(s) located
in a native coronary artery with
diameter of ≥2.0mm.
3. Subjects with LVEF <30%
4. Target lesion(s) amenable for PCI
with balloon angioplasty of the side
branch.
4. Subjects with moderate or severe
degree valvular heart disease or
primary cardiomyopathy
5. Distal LM stenosis
6. Bifurcation lesions requiring a priori
2-stent technique
LM= left main stem, PCI=percutaneous coronary intervention.
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times upper limit normal (ULT) increase of troponin, CK-MB, total
CK or MRI-detected new areas of late-gadolinium enhancement,
associated with symptoms suggesting ischemia, and/or appearance
of new-Q waves on surface ECG; target lesion revascularization—
any reintervention in previously implanted stent and/or±5mm
proximal/distal from stent borers; stent thrombosis—according to
Academic Research Consortium definition—definite, probable,
possible; early—1 to 30 days after PCI, late—30 days—12 months
after PCI, very late—after 12 months after initial PCI, stroke—
defined as new persistent neurology deficit, and bleeding—defined
according to TIMI group as major and minor.
An independent Clinical Event Committee is built by 3
cardiologists, who are otherwise not involved in the trial. Each
clinical event will be adjudicated independently and blindly by 2
members of Committee. In case of disagreement, the third
member will be involved and joint agreement should be reached.
2.6. Statistics
The mean incidence of MACE rates with currently available
stents at 1 year is 10% to 15%. Assuming noninferiority margin
(delta) of 8%, a total sample size of 518 patients (with drop-out
rate of 5%), 259 patients per group, will be necessary (type I
error: 0.05, type II error: 0.2, statistical power 80%). During the
analysis, continuous variables in the 2 groups will be compared
by unpaired Student t test, Mann–Whitney test, or analysis of
variance (ANOVA) test, as appropriate. Categorical variables in
the 2 groups will be compared with Fisher exact or Chi-square
tests, as appropriate. Difference in event-free survival between the
2 groups will be evaluated by applying the Kaplan–Meier curves.
Results will be adjusted by Cox-regression multivariate analysis
where needed, as appropriate. A probability value of P< .05 is
considered as statistically significant.
2.7. Data reporting
Central data management will be performed by principle
investigators at the Centre of Postgraduate Medical Education
in Warsaw. Data will be recorded at each site on a case report
form, verified primarily by the local investigator. It is the
investigators’ responsibility to ensure the accuracy, completeness,
and legibility of the data collection. Source documentation should
indicate dates and details of routine examinations, treatment
interventions, and adverse events.
POLBOS 3
Study flow chart
Patients qualified for PCI in coronary bifurcation lesion
Inclusion/Exc lusion criteria met
Randomization 1 : 1 (518 pts)
259 pts 259 pts
BiOSS LI M C group
2nd gen. DES  group
(Orsiro, Resolute, Synergy, Xience only)
Clinical follow-up:
- 30 days
- 6 months
- 12 months
Figure 1. POLBOS 3 flow chart.
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3. Discussion and conclusion
Coronary bifurcations are encountered in about 15% to 20% of
percutaneous coronary interventions. They are considered
technically challenging and associated with worse clinical
outcomes than nonbifurcation lesions. The optimal treatment
is still the matter of debate and the use of dedicated bifurcations
stents is also a matter of discussion.[17,18] The BiOSS LIM C is a
dedicated bifurcation balloon expandable stent made of cobalt-
chromium alloy (strut thickness 70mm) releasing sirolimus (1.4m
g/mm2) from the surface of a biodegradable coating comprised of
a copolymer of lactic and glycolic acids. The aim of the
randomized, multicenter, open-label, controlled POLBOS III trial
is to compare BiOSS LIM Cwith olimus second-generation drug-
eluting stents in the treatment of non-LM coronary bifurcations
(ClinicalTrials.gov NCT03548272).
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